Literature DB >> 23572113

Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?

V Roldán1, F Marín, S Manzano-Fernandez, H Fernández, P Gallego, M Valdés, V Vicente, G Y H Lip.   

Abstract

Chronic Kidney Disease (CKD) constitutes an adverse risk factor in chronic anticoagulated atrial fibrillation (AF) patients, being related to adverse cardiovascular events, mortality and major bleeds. It is unclear if CKD adds independent prognostic information to stroke risk stratification schemes, as the risk factor components of the CHADS2 and CHA2DS2-VASc scores are themselves related to renal dysfunction. The aim of our study was to determine if CKD independently improves the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification scores in AF. We recruited consecutive patients (n=978) patients (49% male; median age 76) with permanent or paroxysmal AF on oral anticoagulants with acenocoumarol, from our out-patient anticoagulation clinic. After a median follow-up of 875 (IQR 706-1059) days, we recorded stroke/transient ischaemic attack (TIA), peripheral embolism, vascular events (acute coronary syndrome, acute heart failure and cardiac death) and all-cause mortality. During follow-up, 113 patients (4.82%/year) experienced an adverse cardiovascular event, of which 39 (1.66%/year) were strokes, 43 (1.83%/year) had an acute coronary syndrome and 32 (1.37%/year) had acute heart failure. Also, 102 patients (4.35%/year) died during the following up, 31 of them (1.32%/year) as a result of a thrombotic event. Based on c-statistics and the integrated discrimination improvement (IDI), CKD did not improve the prediction for stroke/systemic embolism, thrombotic events and all-cause mortality using the CHADS2 and CHA2DS2-VASc scores. In conclusion, evaluating renal function in AF patients is important as CKD would confer a poor overall prognosis in terms of thromboembolic events and all-cause mortality. Adding CKD to the CHADS2 and CHA2DS2-VASc stroke risk scores did not independently add predictive information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572113     DOI: 10.1160/TH13-01-0054

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  Use of novel oral anticoagulants in patients with heart failure.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

Review 2.  Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors:  Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

3.  Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation.

Authors:  Christine Parsons; Stephen Cha; Win-Kuang Shen; Alanna M Chamberlain; Sushil Allen Luis; Mira Keddis; Fadi Shamoun
Journal:  Am J Cardiol       Date:  2018-05-15       Impact factor: 2.778

4.  Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry.

Authors:  Jelena Kornej; Jedrzej Kosiuk; Gerhard Hindricks; Arash Arya; Philipp Sommer; Sascha Rolf; Daniela Husser; Gregory Y H Lip; Andreas Bollmann
Journal:  Clin Res Cardiol       Date:  2015-02-24       Impact factor: 5.460

5.  CHA2DS2-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation.

Authors:  Christine Parsons; Salma I Patel; Stephen Cha; Win-Kuang Shen; Santosh Desai; Alanna M Chamberlain; Sushil Allen Luis; Maria I Aguilar; Bart M Demaerschalk; Farouk Mookadam; Fadi Shamoun
Journal:  Mayo Clin Proc       Date:  2017-03       Impact factor: 7.616

Review 6.  Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy.

Authors:  Brandon W Calenda; Valentin Fuster; Jonathan L Halperin; Christopher B Granger
Journal:  Nat Rev Cardiol       Date:  2016-07-07       Impact factor: 32.419

7.  Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatment.

Authors:  Yun-Li Xing; Qing Ma; Xiao-Ying Ma; Cui-Ying Wang; Zhen Zhou; Ying-Shuo Huang; Ying Sun
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Management of Atrial Fibrillation in Patients With Kidney Disease.

Authors:  Yee C Lau; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

Review 9.  Risk of Ischemic Stroke and Stroke Prevention in Patients with Atrial Fibrillation and Renal Dysfunction.

Authors:  Tze-Fan Chao; Shih-Ann Chen
Journal:  J Atr Fibrillation       Date:  2015-06-30

Review 10.  Stroke Risk Predictor Scoring Systems in Atrial Fibrillation.

Authors:  Tze-Fan Chao M D And; Shih-Ann Chen M D
Journal:  J Atr Fibrillation       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.